- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medigus Announces Fourth Quarter and Fiscal Year 2017 Financial Results
Medigus (NASDAQ:MDGS) a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. As quoted in the press release: Total revenues in the fourth quarter of 2017 were $154,000, an increase of $101,000, or 190% compared …
Medigus (NASDAQ:MDGS) a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
As quoted in the press release:
- Total revenues in the fourth quarter of 2017 were $154,000, an increase of $101,000, or 190% compared to the same period in 2016
- Gross profit in the fourth quarter of 2017 was $80,000, an increase of $49,000, or 163% compared to the same period in 2016
- Research and development expenses in the fourth quarter of 2017 were $464,000, a decrease of $170,000, or 27% compared to the same period in 2016
- Sales and marketing expenses in the fourth quarter of 2017 were $305,000, an increase of $25,000, or 9% compared to the same period in 2016
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.